Initial Combination Therapy with Macitentan and Tadalafil in Patients with Pulmonary Arterial Hypertension, with and Without Cardiac Comorbidities

Overview

Journal Eur J Heart Fail

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 5

PMID 38966990

Authors

Vallerie V McLaughlin

Olivier Sitbon

Kelly M Chin

Nazzareno Galie

Marius M Hoeper

David G Kiely

Gwen MacDonald

Nicolas Martin

Stephen C Mathai

Andrew Peacock

Ahmed Tawakol

Adam Torbicki

Anton Vonk Noordegraaf

Stephan Rosenkranz

Affiliations

Soon will be listed here.

Abstract

Aims: According to current guidelines, initial monotherapy should be considered for pulmonary arterial hypertension (PAH) patients with cardiopulmonary comorbidities. This analysis of combined data from the TRITON and REPAIR clinical trials, assesses efficacy and safety of initial double combination therapy in patients without vs. with 1-2 cardiac comorbidities.

Methods And Results: Data were combined for patients from TRITON (NCT02558231) and REPAIR (NCT02310672) on initial macitentan and tadalafil double combination therapy (overall set, n = 148) and two subgroups defined as patients without cardiac comorbidities (n = 62) and those with 1-2 cardiac comorbidities (n = 78). Patients with ≥3 comorbidities were excluded from these studies. For the overall set, the median (Q1-Q3) duration of combined macitentan and tadalafil exposure was 513.0 (364.0-778.0) days, and was similar between subgroups. Change from baseline to Week 26 for pulmonary vascular resistance was -55% and -50% for patients without and with 1-2 cardiac comorbidities, respectively; marked improvements in other hemodynamic and functional parameters were also observed, although functional parameters improved to a lesser extent in patients with comorbidities. At Week 26, the majority of patients had improved PAH risk status, according to the non-invasive four-strata and REVEAL Lite 2.0 methods. The safety profile of initial macitentan plus tadalafil combination therapy was consistent with the known profiles of the two drugs, and similar between the subgroups.

Conclusions: Initial double combination therapy with macitentan plus tadalafil is efficacious in patients with PAH with 1-2 cardiac comorbidities and those without, with similar safety and tolerability profiles between the two groups.

References

Radegran G, Kjellstrom B, Ekmehag B, Larsen F, Rundqvist B, Blomquist S . Characteristics and survival of adult Swedish PAH and CTEPH patients 2000-2014. Scand Cardiovasc J. 2016; 50(4):243-50. DOI: 10.1080/14017431.2016.1185532. View

Hassoun P, Zamanian R, Damico R, Lechtzin N, Khair R, Kolb T . Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015; 192(9):1102-10. PMC: 4642204. DOI: 10.1164/rccm.201507-1398OC. View

Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L . Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020; 56(3). PMC: 7469971. DOI: 10.1183/13993003.00673-2020. View

Chin K, Sitbon O, Doelberg M, Feldman J, Gibbs J, Grunig E . Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021; 78(14):1393-1403. DOI: 10.1016/j.jacc.2021.07.057. View

Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grunig E . COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2021; 60(1). PMC: 9260123. DOI: 10.1183/13993003.02311-2021. View

Rosenkranz S, Pausch C, Coghlan J, Huscher D, Pittrow D, Grunig E . Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. J Heart Lung Transplant. 2022; 42(1):102-114. DOI: 10.1016/j.healun.2022.10.003. View

Ling Y, Johnson M, Kiely D, Condliffe R, Elliot C, Gibbs J . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012; 186(8):790-6. DOI: 10.1164/rccm.201203-0383OC. View

Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S . A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017; 39(47):4175-4181. DOI: 10.1093/eurheartj/ehx257. View

Galie N, Barbera J, Frost A, Ghofrani H, Hoeper M, McLaughlin V . Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(9):834-44. DOI: 10.1056/NEJMoa1413687. View

10.

Frost A, Badesch D, Barst R, Benza R, Elliott C, Farber H . The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2010; 139(1):128-37. DOI: 10.1378/chest.10-0075. View

11.

Hoeper M, Kramer T, Pan Z, Eichstaedt C, Spiesshoefer J, Benjamin N . Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00740-2017. View

12.

Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prevot G . External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2021; 59(6). PMC: 9245192. DOI: 10.1183/13993003.02419-2021. View

13.

Hoeper M, Pausch C, Grunig E, Klose H, Staehler G, Huscher D . Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant. 2020; 39(12):1435-1444. DOI: 10.1016/j.healun.2020.09.011. View

14.

Benza R, Kanwar M, Raina A, Scott J, Zhao C, Selej M . Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2020; 159(1):337-346. PMC: 7462639. DOI: 10.1016/j.chest.2020.08.2069. View

15.

Hjalmarsson C, Radegran G, Kylhammar D, Rundqvist B, Multing J, Nisell M . Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J. 2018; 51(5). DOI: 10.1183/13993003.02310-2017. View

16.

Hoeper M, McLaughlin V, Barbera J, Frost A, Ghofrani H, Peacock A . Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016; 4(11):894-901. DOI: 10.1016/S2213-2600(16)30307-1. View

17.

Wissmuller M, Xanthouli P, Benjamin N, Grunig E, Richter M, Gall H . Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres. ESC Heart Fail. 2022; 9(5):2873-2885. PMC: 9715885. DOI: 10.1002/ehf2.13804. View

18.

Rosenkranz S, Channick R, Chin K, Jenner B, Gaine S, Galie N . The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail. 2021; 24(1):205-214. PMC: 9298818. DOI: 10.1002/ejhf.2369. View

19.

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022; 61(1). DOI: 10.1183/13993003.00879-2022. View

20.

Badagliacca R, DAlto M, Ghio S, Argiento P, Brunetti N, Casu G . Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension. ERJ Open Res. 2022; 8(4). PMC: 9638831. DOI: 10.1183/23120541.00298-2022. View